Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia

Autologous T cells engineered to express a chimeric antigen receptor (CAR) against the CD19 antigen are in the frontline of contemporary hemato-oncology therapies, leading to high remission rates in B-cell malignancies. Although effective, major obstacles involve the complex and costly individualize...

Descripción completa

Detalles Bibliográficos
Autores principales: Rozenbaum, Meir, Meir, Amilia, Aharony, Yarden, Itzhaki, Orit, Schachter, Jacob, Bank, Ilan, Jacoby, Elad, Besser, Michal J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343910/
https://www.ncbi.nlm.nih.gov/pubmed/32714329
http://dx.doi.org/10.3389/fimmu.2020.01347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343910/
https://www.ncbi.nlm.nih.gov/pubmed/32714329
http://dx.doi.org/10.3389/fimmu.2020.01347

Ejemplares similares